[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584447":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":10,"centralContacts":44,"locations":50,"responsibleParty":67,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Attikon Hospital","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1 agonists",null,"30 women will receive lifestyle modification and GLP-1RA.",[13],"Drug: GLP-1 receptor agonist",{"label":15,"type":10,"description":16,"interventionNames":17},"Oral contraceprives","30 women will receive lifestyle modification and OCP.",[18],"Drug: Oral contraceptive",{"label":20,"type":10,"description":21,"interventionNames":22},"Metformin","30 women will receive lifestyle modification and metformin",[23],"Drug: Metformin",{"label":25,"type":10,"description":26,"interventionNames":27},"Lifestyle Modification","30 women will receive only lifestyle modification",[28],"Other: Lifestyle modification",[30,35,39,41],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"DRUG","GLP-1 receptor agonist","30 women will receive lifestyle modification and GLP-1 receptor agonists",[9],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Oral contraceptive","30 women will receive lifestyle modification and oral contraceptive",[15],{"type":31,"name":20,"description":21,"armGroupLabels":40,"otherNames":10},[20],{"type":6,"name":42,"description":26,"armGroupLabels":43,"otherNames":10},"Lifestyle modification",[25],[45],{"name":46,"role":47,"phone":48,"phoneExt":10,"email":49},"VAIA lAMBADIARI, Professor","CONTACT","2105831148","vlambad@otenet.gr",[51],{"facility":52,"status":53,"city":54,"state":10,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Attikon University General Hospital","RECRUITING","Chaïdári","124 62","Greece","GR",{"type":59,"coordinates":60},"Point",[61,62],23.66597,38.01135,{"lat":62,"lon":61},[65],{"name":66,"role":47,"phone":48,"phoneExt":10,"email":49},"Vaia Lambadiari, Professor",{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","VAIA LAMBADIARI","Professor of Internal Medicine-Endocrinology","100584447","cardiovascular-and-endothelial-markers-during-ogtt-before-and-at-six-and-twelve-months-post-treatment-in-women-with-pcos-100584447",false,"NCT06889454","Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS","The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome","Inclusion Criteria:\n\n1. Age \\> 16 years old\n2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:\n\n   * Clinical or biochemical hyperandrogenism\n   * Anovulation or oligo-ovulation\n   * Polycystic ovarian morphology (PCOM)\n3. Absence of treatment for PCOS the last six months\n4. Patients who have the ability to understand and sign the consent form.\n\nExclusion Criteria:\n\n1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \\[17-OHP\\]), Cushing syndrome, acromegaly\n2. Treatment with contraceptive or metformin\n3. Type 2 diabetes mellitus\n4. Treatment for diabetes\n5. Pregnancy\n6. Lactation\n7. Malignancy","FEMALE","18 Years","45 Years",{"count":82,"type":83},120,"ESTIMATED","OBSERVATIONAL","The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.",[87,88,89,90],"PCOS","Hyperinsulinism","Hyperandrogenism","Metabolic Syndrome","2025-11-15",{"date":93,"type":94},"2025-11-19","ACTUAL",{"date":96,"type":94},"2024-02-01",{"date":98,"type":83},"2026-02-01",{"name":5,"class":6},1]